Doripenem versus bacteria: an emerging battleground

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Doripenem is a new carbapenem antibiotic with broad-spectrum activity.
• Its efficacy is comparable to existing carbapenems like imipenem, ertapenem, and meropenem against key pathogens.
• Unlike some carbapenems, doripenem does not require cilastatin for administration.

Purpose of the Study:

• To evaluate the in vitro activity and stability of doripenem against clinically relevant bacteria.
• To compare doripenem's activity with other carbapenems.
• To investigate doripenem's stability against carbapenem-hydrolyzing beta-lactamases.

Main Methods:

• In vitro susceptibility testing against Gram-positive and Gram-negative bacteria.
• Molecular docking simulations of doripenem and other carbapenems with imipenem-hydrolyzing beta-lactamase (Sme1).
• Energy calculations to assess complex stability.

Main Results:

• Doripenem exhibits broad-spectrum activity, matching imipenem/ertapenem against Gram-positive and meropenem against Gram-negative bacteria.
• Doripenem is stable against most beta-lactamases, with molecular docking suggesting reduced susceptibility to carbapenem-hydrolyzing beta-lactamases.
• Docking revealed significantly less stable complexes for doripenem with Sme1 compared to other carbapenems.

Conclusions:

• Doripenem demonstrates potent broad-spectrum antibacterial activity and stability against common beta-lactamases.
• Its reduced susceptibility to carbapenem-hydrolyzing beta-lactamases suggests a potential role in treating infections caused by resistant pathogens.
• Further clinical studies are needed to define doripenem's optimal role in antibiotic therapy for multidrug-resistant infections.